Renal Cancer - Results from #1660

Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor. January 28, 2022

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery January 27, 2022

Pyroptosis Regulators and Tumor Microenvironment Infiltration Characterization in Clear Cell Renal Cell Carcinoma. January 27, 2022

Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists. January 27, 2022

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment. January 26, 2022

Association of Extrarenal Invasion Patterns and Tumor Size with the Differences in Survival Outcomes of T3a Renal Cell Carcinoma: A Proposal Modified T3a Stage System is Needed. January 26, 2022

Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response. January 25, 2022

High efficiency capture of biomarker miRNA15a for noninvasive diagnosis of malignant kidney tumors. January 25, 2022

Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy? January 24, 2022

The effect of frailty on post-operative outcomes and health care expenditures in patients treated with partial nephrectomy. January 24, 2022

IL-1A is associated with postoperative survival and immune contexture in clear cell renal cell carcinoma. January 21, 2022

Quantification of T- and B-cell immune receptor distribution diversity characterizes immune cell infiltration and lymphocyte heterogeneity in clear cell renal cell carcinoma. January 21, 2022

A Bioinformatic Analysis of Immune-Related Prognostic Genes in Clear Cell Renal Cell Carcinoma Based on TCGA and GEO Databases. January 20, 2022

NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases. January 20, 2022

Risk of recurrence after nephrectomy: Comparison of predictive ability of validated risk models. January 19, 2022

Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. January 19, 2022

Risk-group Classification by Recursive Partitioning Analysis of Patients Affected by Oligometastatic Renal Cancer Treated with Stereotactic Radiotherapy. January 18, 2022

Surgical outcomes for older patients with renal cell carcinoma and inferior vena cava thrombus. January 18, 2022

Thermal Ablation Combined with Selective Transarterial Embolization of Centrally Located Renal Cell Carcinomas Measuring 3 cm or Larger. January 17, 2022

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. January 17, 2022

Page 84 of 456